Drugs / HB-adMSCs
HB-adMSCs
Trials 26
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2026-03-28 | Hope Biosciences Research Foundation | Regulatory Multiple System Atrophy: A case study in hope for rare diseases hope.bio ↗ |
| 2025-09-10 | Hope Biosciences Research Foundation | Regulatory Hope Bio’s stem cells zero in on Crohn’s Disease hope.bio ↗
The U.S. Food and Drug Administration (FDA) has authorized a Phase II clinical trial to evaluate whether the stem cells manufactured through Hope’s proprietary technology affect signs and symptoms of Crohn’s Disease in suffering people. |
| 2025-06-12 | Hope Biosciences Research Foundation | Regulatory Hope Bio hope.bio ↗
The U.S. Food and Drug Administration (FDA) has authorized an open label Phase Ib/IIa clinical trial to evaluate whether Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce inflammation in the brain, improve brain activity, and/or slow progression of AD. |
| 2024-11-01 | Hope Biosciences Research Foundation | Results Hope Biosciences Shares Promising Topline Results in Multiple Sclerosis hope.bio ↗ |
| 2023-09-13 | Hope Biosciences Research Foundation | Results The Leo Effect: Why Hope Bio hope.bio ↗
Multi-dose treatment with autologous stem cells cultured by Hope Biosciences’ proprietary methods (referred to as “HB-adMSCs”) may offer a safe and effective way to improve quality of life in patients with cerebral palsy . |
| 2022-03-08 | Hope Biosciences Research Foundation | Results Hope Biosciences’ Cell Therapy Shown Safe, Beneficial for Rheumatoid Arthritis hope.bio ↗
Administration of HB-adMSCs resulted in a favorable safety profile, significant and persistent improvements in joint functions, and modest improvements in inflammatory marker C-reactive protein (CRP). |
| 2021-06-21 | Hope Biosciences Research Foundation | Regulatory TWO CLINICAL TRIALS, 85 BILLION STEM CELLS, AND A WHOLE LOT OF HOPE IN THE FIGHT AGAINST PARKINSON’S hope.bio ↗
Last week HBSCRF received FDA authorization for a second Phase II trial in Parkinson’s Disease, this time using allogeneic adipose-derived mesenchymal stem cells, also thought of as donor cells. |
| 2021-04-27 | Hope Biosciences Research Foundation | Regulatory HOPE BIO’S STEM CELLS TO BE USED IN FIGHT AGAINST PARKINSON’S hope.bio ↗
This week Hope Biosciences Stem Cell Research Foundation received FDA authorization for a Phase II clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving activities of daily living and quality of life in subjects with Parkinson’s Disease. |
| 2020-04-21 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Announces Third FDA-approved Clinical Trial for COVID-19 hope.bio ↗
Hope Biosciences announces FDA approval on their third clinical trial for COVID-19. |
| 2020-04-13 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Receives Second FDA Clearance for a Phase II Clinical Trial for COVID-19 hope.bio ↗ |
| 2020-04-06 | Hope Biosciences Research Foundation | Regulatory Stem Cell FDA approved trial hope.bio ↗
today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19. |
| 2019-11-20 | Hope Biosciences Research Foundation | Regulatory Hope Biosciences Receives FDA Approval to Commence Groundbreaking Clinical Trial for Alzheimer hope.bio ↗ |
All press releases naming this drug 12 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-adMSCs | “multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of nontraumatic or traumatic brain injury” NCT07164482 ↗27“multiple intravenous administrations of autologous HB-adMSCs for the treatment of Parkinson's disease” NCT06056427 ↗ “Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)” NCT06623240 ↗ |
| Known as | allogeneic adipose-derived mesenchymal stem cells | “Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide...” NCT04348435 ↗ |
| Known as | autologous adipose-derived mesenchymal stem cells | “investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs)” NCT04228666 ↗ |
| Known as | HB-adMSC | “This protocol utilized Hope Biosciences' autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to evaluate safety and efficacy of HB-adMSC therapy to improve signs and...” PMID 37798650 ↗ Oct 2023 |
| Known as | Hope Biosciences adipose derived mesenchymal stem cells | “This study is a prospective, randomized, double-blind, placebo-controlled Phase 2a study of three infusions of autologous HB-adMSCs (Hope Biosciences adipose-derived...” NCT05951777 ↗4“HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)” NCT07164482 ↗ “HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)” NCT06056427 ↗ “HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells” NCT07077746 ↗ “HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells” NCT07238062 ↗ |
| Modality | Cell therapy | “autologous adipose-derived mesenchymal stem cells (HB-adMSCs)” NCT03691909 ↗ |
| Route | Intravenous | “A single IV infusion of autologous adipose-derived mesenchymal stem cells (HB-adMSCs)” NCT03691909 ↗ |